Literature DB >> 12084417

Typical antipsychotic drugs -- D(2) receptor occupancy and depressive symptoms in schizophrenia.

Rodrigo A Bressan1, Durval C Costa, Hugh M Jones, Peter J Ell, Lyn S Pilowsky.   

Abstract

We tested the hypothesis that the degree of striatal dopamine D(2) receptor blockade induced by typical antipsychotic treatment directly correlates with the presence and severity of depressive symptoms in schizophrenia. Clinical and [(123)I]-IBZM single-photon emission tomography (SPET) scan data obtained from 18 typical antipsychotic treated schizophrenic patients was analysed to evaluate the relationship between striatal D(2) receptor occupancy and the depressive subscale of the Brief Psychiatric Rating Scale (BPRS-D). Striatal D(2) receptor occupancy by typical antipsychotic drugs was significantly positively correlated with BPRS-D scores (r=0.52, p=0.025). This study suggests that high striatal dopamine D(2) blockade by typical antipsychotic drugs may contribute to the emergence of depressive symptoms in typical antipsychotic treated schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084417     DOI: 10.1016/s0920-9964(01)00185-2

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  14 in total

Review 1.  Elderly patients with schizophrenia and depression: diagnosis and treatment.

Authors:  Kandi Felmet; Sidney Zisook; John W Kasckow
Journal:  Clin Schizophr Relat Psychoses       Date:  2011-01

Review 2.  Cognitive effects of second-generation antipsychotics: current insights into neurochemical mechanisms.

Authors:  Fabio Fumagalli; Angelisa Frasca; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

3.  Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.

Authors:  Tanja Veselinović; Holger Schorn; Ingo Vernaleken; Katharina Schiffl; Christoph Hiemke; Gerald Zernig; Ruben Gur; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2011-06-04       Impact factor: 4.530

Review 4.  Co-occurring depressive symptoms in the older patient with schizophrenia.

Authors:  John W Kasckow; Sidney Zisook
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

5.  Impact of depression and social support on nonadherence to antipsychotic drugs in persons with schizophrenia in Thailand.

Authors:  Sirijit Suttajit; Sutrak Pilakanta
Journal:  Patient Prefer Adherence       Date:  2010-10-05       Impact factor: 2.711

Review 6.  Meta-Analysis of the COMT Val158Met Polymorphism in Major Depressive Disorder: Effect of Ethnicity.

Authors:  Maiqiu Wang; Yunlong Ma; Wenji Yuan; Kunkai Su; Ming D Li
Journal:  J Neuroimmune Pharmacol       Date:  2016-01-23       Impact factor: 4.147

Review 7.  Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

Authors:  O D Howes; A Egerton; V Allan; P McGuire; P Stokes; S Kapur
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Genetically determined dopamine availability predicts disposition for depression.

Authors:  Andrea Felten; Christian Montag; Sebastian Markett; Nora T Walter; Martin Reuter
Journal:  Brain Behav       Date:  2011-11       Impact factor: 2.708

9.  The dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers.

Authors:  John Liggins; Robert O Pihl; Chawki Benkelfat; Marco Leyton
Journal:  PLoS One       Date:  2012-01-04       Impact factor: 3.240

10.  Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D2 Receptor Occupancy: Unique Characteristics of Blonanserin Transdermal Patch.

Authors:  Yoshiko Tomita; Takeshi Takagaki; Atsushi Kitamura; Erika Wada; Hironori Nishibe; Amane Tateno; Yoshiro Okubo
Journal:  J Clin Psychopharmacol       Date:  2022-04-05       Impact factor: 3.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.